Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq: OCUL) concerning possible violations of federal securities laws.
If you purchased shares of Ocular and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
The investigation concerns whether Ocular and certain of its directors and/or officers violated federal securities laws. On May 5, 2017, the Company disclosed that it received a Form 483 from the Food and Drug Administration containing “inspectional observations” related to the Company’s manufacturing and analytical testing procedures. On July 6, 2017, a report was published on SeekingAlpha.com alleging that Ocular’s management had been misleading investors regarding the severity of the Company’s manufacturing troubles. When this news was announced, shares of Ocular fell in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esquire, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170707005690/en/
Contacts:
Joon M. Khang, Esq.
Telephone:
949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
